Protalix BioTherapeutics, Inc. (PLX)
NYSEAMERICAN: PLX · Real-Time Price · USD
2.370
+0.050 (2.16%)
At close: Aug 4, 2026, 4:00 PM EDT
2.370
0.00 (0.00%)
After-hours: Aug 4, 2026, 4:10 PM EDT

Protalix BioTherapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.

Total Valuation

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Aug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
1911451431307438
Market Cap Growth
65.47%1.52%9.81%76.21%94.49%-69.98%
Enterprise Value
148.35122.81113.29111.5884.9932.37
Last Close Price
2.371.801.881.781.370.83

Price Ratios

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Aug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
12.27-47.0019.78--
Forward PE
-10.293.9413.1760.89111.67
PS Ratio
2.502.742.671.981.550.99
PB Ratio
2.843.003.303.87-6.93-6.28
P/TBV Ratio
2.862.933.534.37--
P/FCF Ratio
14.69-19.29---
P/OCF Ratio
12.65-16.44---

EV Ratios

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Aug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
EV/Sales Ratio
1.942.332.121.701.780.84
EV/EBITDA Ratio
6.96-21.709.58--
EV/EBIT Ratio
7.50-28.9210.67--
EV/FCF Ratio
11.41-15.33---

Financial Efficiency

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Aug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Debt / Equity Ratio
0.100.140.090.14-3.04-5.35
Debt / EBITDA Ratio
0.40-1.062.26--
Debt / FCF Ratio
0.65-0.75---
Net Debt / Equity Ratio
-0.63-0.45-0.68-0.55-1.060.91
Net Debt / EBITDA Ratio
-2.005.44-5.61-1.57-0.950.28
Net Debt / FCF Ratio
-3.281.61-3.967.41-0.440.47
Asset Turnover
0.830.680.680.930.740.54
Inventory Turnover
0.821.151.211.281.131.05
Quick Ratio
1.971.471.471.090.831.28
Current Ratio
3.152.512.341.541.381.86
Return on Equity (ROE)
30.01%-10.09%14.00%76.93%166.31%166.80%
Return on Assets (ROA)
19.27%-5.81%6.42%15.36%-19.37%-28.90%
Return on Invested Capital (ROIC)
69.92%-22.51%34.73%55.73%-39.27%-186.45%
Return on Capital Employed (ROCE)
30.27%-10.62%9.04%33.60%-40.77%-186.45%

Yields

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Aug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Earnings Yield
8.03%-2.13%5.06%--
FCF Yield
6.81%-5.18%---
Buyback Yield / Dilution
2.19%3.10%1.66%-70.04%-9.81%-51.43%
Total Shareholder Return
2.19%3.10%1.66%-70.04%-9.81%-51.43%
SEC Filings: 10-K · 10-Q